AG百家乐代理-红桃KAG百家乐娱乐城

Research News

Nature Reviews Drug Discovery: targeting cancer-associated fibroblasts

Share
  • Updated: Dec 24, 2018
  • Written:
  • Edited:
Source: Sun Yat-sen Memorial Hospital
Written by: Xueman Chen
Edited by: Wang Dongmei

Recently, a Review Article entitled “Turning foes to friends: targeting cancer-associated fibroblasts” was published online in Nature Reviews Drug Discovery (IF 2018=50.17)1. Professor Erwei Song, President of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, is the corresponding author, and Xueman Chen, a PhD student from his team, is the first author.

Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance. In the past decade, a burst of knowledge on how the tumor microenvironment (TME) interacts with tumor cells has urged studies on a new cancer treatment paradigm: targeting the tumor stroma. Among all the stromal cells that populate the TME, cancer-associated fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression, which render them as conspicuous stromal targets in many, if not all, solid tumors. However, without unequivocal cell-surface markers, live-cell sorting for functional and mechanistic studies on CAFs in vitro and targeting therapies towards CAFs in vivo are greatly hindered.

It is noteworthy that a previous research from Prof. Erwei Song’s team revealed CD10 and GPR77 as two specific cell-surface makers for a novel pro-tumorigenic CAF subset involved in cancer stemness and chemoresistance2. More importantly, GPR77 is a functional marker which can be directly targeted for in vivo CAF depletion. The restoration of chemosensitivity of tumor cells upon GPR77 blockade further suggests the remarkable therapeutic value of such a precise CAF-targeted strategy for cancers.


Accumulated molecular characterization of CAFs not only deepens our insights into their phenotypic heterogeneity and functional diversity, but also brings CAF-targeting therapies for cancer treatment onto the agenda. However, translating the basic research into clinical practice takes tremendous efforts and is extremely time-consuming, which makes it an urgent need for therapists and drug developers to comprehensively recognize the functional significance and molecular mechanisms of CAFs in cancers.

In this Review, Prof. Song’s team presented a full-scale overview regarding the current understanding of the hallmarks, biology and heterogeneity of CAFs, highlighting the CAF-centered intercellular crosstalk within the TME, and discussed multipronged functions of CAFs in tumor initiation, progression, metastasis and resistance to anticancer therapies. Prof. Song’s team also elaborated on the potential therapeutic strategies targeting CAFs, with an aim to accelerate the leap from bench to bedside.


References
1.  Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery (2018).
2.  Su, S., et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell (2018).

Link to the review article: www.nature.com/articles/s41573-018-0004-1
TOP
百家乐什么牌最大| 太阳城百家乐官网分析解码| 百家乐官网技巧开户| 百家乐23珠路打法| 广东百家乐官网扫描分析仪| 百家乐赢利策略| 8大胜娱乐| 网上百家乐如何打水| 盘锦市| 正品百家乐官网游戏| 大发888官方6222.c| 风水24山图片| 菲律宾太子娱乐城| 百家乐官网博娱乐平台赌百家乐官网 | 百家乐轮盘技巧| 百家乐官网2万| 威尼斯人娱乐场 28| 百家乐官网视频交流| 劳力士百家乐的玩法技巧和规则| 百家乐官网闲庄和| 百樂坊百家乐的玩法技巧和规则| 扑克王百家乐官网的玩法技巧和规则| 狮威国际娱乐| 网络百家乐官网怎么作弊| 蓝盾百家乐官网平台租用| 绵竹市| 百家乐官网博彩破解论坛| 威尼斯人娱乐城百家乐赌博| 百家乐官网公式与赌法| 伟博娱乐| 在线百家乐博彩| 百家乐官网园sun811| 班戈县| bet365体育开户| 乐宝百家乐的玩法技巧和规则| 百家乐官网号破| 澳门百家乐官网破解方法| 大发888游戏秘籍| 百家乐投注规则| 百家乐官网园百利宫娱乐城怎么样百家乐官网园百利宫娱乐城如何 | 名人线上娱乐城|